Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
The FDA granted RMAT (regenerative medicine advanced therapy) designation to Autolus Therapeutics' CAR-T therapy obe-cel for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The designation, created under the 21st Century Cures Act, was granted based on Phase 1b data from the CARLYSLE trial and provides a framework for more efficient development within the pivotal Phase 2 LUMINA study.
Key figures
- Drug Name
- obe-cel (obecabtagene autoleucel)
- Phase Of Trial
- pivotal Phase 2 (LUMINA); Phase 1b data (CARLYSLE)
- Designation
- RMAT (regenerative medicine advanced therapy)
- Pivotal Data Year
- 2028
- Next Data Catalyst
- CARLYSLE Phase 1 SLE data update submitted for ACR Annual Meeting presentation, Q4 2026
- Lumina Enrollment Countries
- 5
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.